Security key
86150R107
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK)
CUSIP: 86150R107
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 65,548,147
- Total 13F value
- $743,993,162
- Share change
- +2,162,250
- SEC-reported price per share
- $11.35
- Number of holders
- 133
- Value change
- +$30,166,679
- Number of buys
- 73
- Number of sells
- 49
- Shares outstanding
- 62,129,292
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
133
Top holders
10
STOK full security history
Ownership snapshot
Full 13F holder table
Stoke Therapeutics, Inc. SEC filings
Stoke Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MORGAN STANLEY
Disclosed value leader
Skorpios Trust
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
3/4/5
Lead comparable stake: 6.5%
13D/G row: MORGAN STANLEY
Showing 1-6 of 15 holder rows.
Quick read
MORGAN STANLEY leads the comparable SEC ownership view at 6.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MORGAN STANLEY's linked filing trail.
Comparable ownership
Top 5
MORGAN STANLEY
6.5%
BlackRock Portfolio Management LLC
4.7%
Skorpios Trust
6.3%
BlackRock, Inc.
9.4%
Lynx1 Capital Management LP
8.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MORGAN STANLEY |
13D/G
13F
Company
|
6.5%
|
$32,588,288
3,426,739 shares
|
$0 | 31 Dec 2024 |
| BlackRock Portfolio Management LLC |
13D/G
|
4.7%
|
$28,946,115
2,550,341 shares
|
-$2,192,358 | 30 Jun 2025 |
| Skorpios Trust |
13F
3/4/5
Company · 10%+ Owner
|
6.3%
from 3/4/5
|
$45,926,104
6,906,181 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
9.4%
|
$38,985,198
5,862,436 shares
|
— | 31 Mar 2025 |
| Lynx1 Capital Management LP |
13F
Company
|
8.5%
|
$35,191,328
5,291,929 shares
|
— | 31 Mar 2025 |
| RTW INVESTMENTS, LP |
13F
Company
|
8.2%
|
$34,071,441
5,123,525 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
133
Shares
65,548,147
Rows available
133
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
124
Q2 2025 holders
133
Holder diff
9
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|